ARCHIMED acquires Jeisys Medical, a leading developer of aesthetic medicine devices, to capitalize on growth opportunities in the expanding South Korean market.

Information on the Target

Jeisys Medical is a prominent developer specializing in aesthetic medicine devices. The company is recognized for its innovative technology and commitment to enhancing the field of non-invasive procedures. Jeisys Medical has carved out a strong reputation with a diverse portfolio of medical devices aimed at delivering effective and safe treatments for various aesthetic concerns.

Since its inception, Jeisys Medical has demonstrated significant growth potential, marked by its dedication to research and development in aesthetic technologies. The company's strategic positioning within the industry has facilitated its expansion both domestically in South Korea and potentially in international markets.

Industry Overview in South Korea

The aesthetic medicine industry in South Korea is experiencing rapid growth, driven by an increasing demand for cosmetic procedures and advanced medical technology. South Korea has become a global leader in beauty and wellness, reco

View Source

Similar Deals

DKSH Molecular Diagnostics Korea Inc. (MDxK)

2025

Buyout In-Vivo Diagnostic & Testing Substances South Korea
DKSH Molecular Diagnostics Korea Inc.

2025

Buyout Bio Diagnostics & Testing South Korea
DKSH MDxK

2025

Buyout In-Vivo Diagnostic & Testing Substances South Korea
Lunit Prognosia

Buyout Bio Diagnostics & Testing South Korea
Bambu Ventures Lemonaid Health

2026

Buyout Advanced Medical Equipment & Technology (NEC) United States of America
Medibank Better Medical

2026

Buyout Hospitals, Clinics & Primary Care Services Australia

ARCHIMED

invested in

Jeisys Medical

in

in a Buyout deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert